Literature DB >> 6334018

Activation and proliferation signals in mouse B cells. III. Intact (IGG) anti-immunoglobulin antibodies activate B cells but inhibit induction of DNA synthesis.

G G Klaus, C M Hawrylowicz, M Holman, K D Keeler.   

Abstract

Intact (IgG) rabbit anti-immunoglobulin antibodies are generally not mitogenic for mouse B cells but, on the contrary, inhibit proliferation induced by either F(ab')2 anti-Ig or by lipopolysaccharide. We show here, however, that IgG anti-Ig activates mouse B cells, since it causes B cells to depolarize, to enlarge and to express increased levels of Ia antigens. In the continuing presence of IgG anti-Ig, B cells do not synthesise DNA. However, if cells cultured with IgG antibody are then washed, they start to proliferate earlier in response to F(ab')2 anti-Ig, i.e. they have become primed. We therefore conclude that IgG anti-Ig is an example of a 'step-one activator' for mouse B cells, which drives resting B cells out of Go, but actively prevents the cells from progressing into S. The latter effect appears to result from cross-linking of surface Ig and Fc receptors on B cells, although the mechanism is, as yet, unknown.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6334018      PMCID: PMC1454868     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  27 in total

1.  Estimation of membrane potentials of individual lymphocytes by flow cytometry.

Authors:  H M Shapiro; P J Natale; L A Kamentsky
Journal:  Proc Natl Acad Sci U S A       Date:  1979-11       Impact factor: 11.205

2.  Anti-immunoglobulin stimulation of murine lymphocytes. V. Age-related decline in Fc receptor-mediated immunoregulation.

Authors:  D J Scribner; H L Weiner; J W Moorhead
Journal:  J Immunol       Date:  1978-07       Impact factor: 5.422

3.  Macrophage requirements for mouse B-cell stimulation differ according to the molecular form of anti-IgM antibodies.

Authors:  M Hattori; D J Scribner; J W Moorhead
Journal:  Nature       Date:  1979-07-26       Impact factor: 49.962

4.  Accessory cell requirement for anti-IgM-induced proliferation of B lymphocytes.

Authors:  P Mongini; S Friedman; H Wortis
Journal:  Nature       Date:  1978-12-14       Impact factor: 49.962

5.  T-cell-dependent B-cell stimulation is H-2 restricted and antigen dependent only at the resting B-cell level.

Authors:  J Andersson; M H Schreier; F Melchers
Journal:  Proc Natl Acad Sci U S A       Date:  1980-03       Impact factor: 11.205

Review 6.  The Fc-receptor: its role in the transmission of differentiation signals.

Authors:  E Kölsch; J Oberbarnscheidt; K Brüner; J Heuer
Journal:  Immunol Rev       Date:  1980       Impact factor: 12.988

7.  Inhibition of mitogenic stimulation of mouse lymphocytes by anti-mouse immunoglobulin antibodies. I. Mode of action.

Authors:  J Andersson; W W Bullock; F Melchers
Journal:  Eur J Immunol       Date:  1974-11       Impact factor: 5.532

8.  Regulation of the immune response. V. An analysis of the function of the Fc portion of antibody in suppression of an immune response with respect to interaction with components of the lymphoid system.

Authors:  P L Chan; N R Sinclair
Journal:  Immunology       Date:  1971-12       Impact factor: 7.397

9.  Anti-immunoglobulin stimulation of murine lymphocytes. I. Age dependency of the proliferative response.

Authors:  H L Weiner; J W Moorhead; H N Claman
Journal:  J Immunol       Date:  1976-06       Impact factor: 5.422

10.  Control of B-lymphocyte function. I. Inactivation of mitogenesis by interactions with surface immunoglobulin and Fc-receptor molecules.

Authors:  C L Sidman; E R Unanue
Journal:  J Exp Med       Date:  1976-10-01       Impact factor: 14.307

View more
  18 in total

1.  Activation and proliferation signals in mouse B cells. VII. Calcium ionophores are non-mitogenic polyclonal B-cell activators.

Authors:  G G Klaus; M K Bijsterbosch; M Holman
Journal:  Immunology       Date:  1985-10       Impact factor: 7.397

2.  Activation and proliferation signals in mouse B cells. VI. Anti-Ig antibodies induce dose-dependent cell cycle progression in B cells.

Authors:  G G Klaus; C M Hawrylowicz; C J Carter
Journal:  Immunology       Date:  1985-07       Impact factor: 7.397

Review 3.  Functional B-lymphocyte surface antigens.

Authors:  J T Golay
Journal:  Immunology       Date:  1986-09       Impact factor: 7.397

4.  Control of human B-lymphocyte replication. I. Characterization of novel activation states that precede the entry of G0 B cells into cycle.

Authors:  L Walker; G Guy; G Brown; M Rowe; A E Milner; J Gordon
Journal:  Immunology       Date:  1986-08       Impact factor: 7.397

5.  Activation and proliferation signals in mouse B cells. V.A. comparison of the effects of intact (IgG) and F (ab')2 anti-mu or anti-delta antibodies.

Authors:  G G Klaus; M K Bijsterbosch; R M Parkhouse
Journal:  Immunology       Date:  1985-04       Impact factor: 7.397

6.  Activation of Ca2+-dependent K+ channels in human B lymphocytes by anti-immunoglobulin.

Authors:  S L MacDougall; S Grinstein; E W Gelfand
Journal:  J Clin Invest       Date:  1988-02       Impact factor: 14.808

7.  Visualization of negative signaling in B cells by quantitative confocal microscopy.

Authors:  H Phee; W Rodgers; K M Coggeshall
Journal:  Mol Cell Biol       Date:  2001-12       Impact factor: 4.272

8.  B-cell-stimulatory factor 1 reverses Fc receptor-mediated inhibition of B-lymphocyte activation.

Authors:  A O'Garra; K P Rigley; M Holman; J B McLaughlin; G G Klaus
Journal:  Proc Natl Acad Sci U S A       Date:  1987-09       Impact factor: 11.205

Review 9.  Cellular signalling mechanisms in B lymphocytes.

Authors:  W Cushley; M M Harnett
Journal:  Biochem J       Date:  1993-06-01       Impact factor: 3.857

10.  Activation and proliferation signals in mouse B cells. IX. Protein kinase C activators synergize with non-mitogenic anti-immunoglobulin antibodies to drive B cells into G1.

Authors:  M K Bijsterbosch; J B McLaughlin; M Holman; G G Klaus
Journal:  Immunology       Date:  1988-05       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.